EPHEDRINE SULFATE injection Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ephedrine sulfate injection

akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injection, usp is indicated in the treatment of allergic disorders, such as bronchial asthma the drug has long been used as a pressor agent, particularly during spinal anesthesia when hypotension frequently occurs. in stokes-adams syndrome with complete heart block, ephedrine has a value similar to that of epinephrine. it is indicated as a central nervous system stimulant in narcolepsy and depressive states. it is also used in myasthenia gravis. allergic reactions to ephedrine sulfate are rare. the hypersensitivity, if known, is a specific contraindication. patients hypersensitive to other sympathomimetics may also be hypersensitive to ephedrine sulfate. prolonged abuse of ephedrine sulfate injection, usp can lead to symptoms of paranoid schizophrenia. when this occurs, patients exhibit such physical signs as tachycardia, poor nutrition and hygiene, fever, cold sweat and dilated pupils. some measure of tolerance may develop with prolonged or excessive use but addiction does not occur. tempor

OFLOXACIN solution/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ofloxacin solution/ drops

akorn - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin 3 mg in 1 ml - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings ).

CHLOROTHIAZIDE SODIUM injection Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

chlorothiazide sodium injection

akorn - chlorothiazide sodium (unii: sn86fg7n2k) (chlorothiazide - unii:77w477j15h) - chlorothiazide sodium for injection is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. chlorothiazide sodium for injection has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see precautions, pregnancy). dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properl

DETOMISED- detomidine hydrochloride solution Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

detomised- detomidine hydrochloride solution

akorn - detomidine hydrochloride (unii: 95k4lkb6qe) (detomidine - unii:7n8k34p2xh) - detomised™ is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. it has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. additionally, an approved, local infiltration anesthetic is indicated for castration. detomised™ should not be used in horses with pre-existing av or sa block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur. information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals.

PHYSOSTIGMINE SALICYLATE injection Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

physostigmine salicylate injection

akorn - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

TROPICAMIDE solution/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

tropicamide solution/ drops

akorn - tropicamide (unii: n0a3z5xtc6) (tropicamide - unii:n0a3z5xtc6) - for mydriasis and cycloplegia for diagnostic procedures. contraindicated in persons showing hypersensitivity to any component of this preparation.

AZELASTINE HYDROCHLORIDE solution/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

azelastine hydrochloride solution/ drops

akorn - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - azelastine hydrochloride ophthalmic solution is indicated for the treatment of itching of the eye associated with allergic conjunctivitis. azelastine hydrochloride ophthalmic solution is contraindicated in persons with known or suspected hypersensitivity to any of its components.

GENTAK- gentamicin sulfate ointment Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

gentak- gentamicin sulfate ointment

akorn - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin sulfate ophthalmic ointment is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharonconjunctivitis: acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: gentamicin sulfate ophthalmic ointment is con-traindicated in patients with known hypersensitivity to any of the components.

PENTOBARBITAL SODIUM AND PHENYTOIN SODIUM injection, solution Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pentobarbital sodium and phenytoin sodium injection, solution

akorn - pentobarbital sodium (unii: njj0475n0s) (pentobarbital - unii:i4744080ir), phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - for use in dogs for humane, painless, and rapid euthanasia.

APRACLONIDINE OPHTHALMIC- apraclonidine hydrochloride solution/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

apraclonidine ophthalmic- apraclonidine hydrochloride solution/ drops

akorn - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 5 mg in 1 ml - apraclonidine ophthalmic solution, usp 0.5% as base is indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional iop reduction. patients on maximally tolerated medical therapy who are treated with apraclonidine ophthalmic solution, usp 0.5% as base to delay surgery should have frequent follow-up examinations and treatment should be discontinued if the intraocular pressure rises significantly. the addition of apraclonidine ophthalmic solution, usp 0.5% as base to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. this is because apraclonidine ophthalmic solution, usp 0.5% as base is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce iop. the iop lowering efficacy of apraclonidine ophthalmic solution, usp 0.5% as base diminishes over time in some patients.